Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

BACKGROUND: Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, upt...

Descripción completa

Detalles Bibliográficos
Autores principales: Jauw, Yvonne W. S., Huisman, Marc C., Nayak, Tapan K., Vugts, Danielle J., Christen, Randolph, Naegelen, Valerie Meresse, Ruettinger, Dominik, Heil, Florian, Lammertsma, Adriaan A., Verheul, Henk M. W., Hoekstra, Otto S., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778091/
https://www.ncbi.nlm.nih.gov/pubmed/29356983
http://dx.doi.org/10.1186/s13550-018-0358-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778091/
https://www.ncbi.nlm.nih.gov/pubmed/29356983
http://dx.doi.org/10.1186/s13550-018-0358-8

Ejemplares similares